CN Patent

CN113677330B — 药物组合物

Assigned to Astellas Pharma Inc · Expires 2023-10-31 · 3y expired

What this patent protects

本发明提供溶出稳定性优良的药物组合物，其含有6‑乙基‑3‑{3‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯胺基}‑5‑[( 烷‑4‑基)氨基]吡嗪‑2‑甲酰胺(吉瑞替尼)或其药学上可接受的盐和降低吉瑞替尼的苦味的甜味剂，抑制例如经时的热和/或湿度等应激所导致的吉瑞替尼的溶出稳定性下降。上述药物组合物含有吉瑞替尼或其药学上可接受的盐、甜味剂、以及糖类和/或糖醇类。

USPTO Abstract

本发明提供溶出稳定性优良的药物组合物，其含有6‑乙基‑3‑{3‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯胺基}‑5‑[( 烷‑4‑基)氨基]吡嗪‑2‑甲酰胺(吉瑞替尼)或其药学上可接受的盐和降低吉瑞替尼的苦味的甜味剂，抑制例如经时的热和/或湿度等应激所导致的吉瑞替尼的溶出稳定性下降。上述药物组合物含有吉瑞替尼或其药学上可接受的盐、甜味剂、以及糖类和/或糖醇类。

Drugs covered by this patent

Patent Metadata

Patent number
CN113677330B
Jurisdiction
CN
Classification
—
Expires
2023-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.